DLBCL

This early-stage trial is testing whether adding an experimental drug called E7777 before standard CAR-T cell therapy can improve results for adults with aggressive B-cell lymphomas that have returned or not responded to prior treatments. The drug aims to help the CAR-T cells wor…

This study is testing a modified, potentially less harsh chemotherapy combination for patients aged 75 and older with an aggressive type of blood cancer called DLBCL. The goal is to see if adding a targeted drug (polatuzumab vedotin) to a reduced-dose standard regimen is effectiv…

This study is testing a new way to give standard chemotherapy (R-CHOP) to older adults with an aggressive type of lymphoma called DLBCL. The goal is to split the doses over two weeks instead of giving them all at once, which researchers hope will be easier for older patients to t…

This study tests whether adding the immunotherapy drug atezolizumab after standard chemotherapy can help prevent cancer from returning in patients with high-risk diffuse large B-cell lymphoma. The trial enrolled 109 adults who had responded well to initial treatment but remain at…

This trial is testing a new antibody drug called epcoritamab in people with B-cell lymphoma that has come back or stopped responding to standard treatments. The main goals are to find the safest and most effective dose, understand the side effects, and see how well the drug works…

This early-phase study is testing an experimental oral medication called MRT-2359 in people with advanced cancers that have run out of standard treatment options. The trial focuses on several types of solid tumors and lymphoma, particularly those driven by specific genes called L…

This study is testing whether adding the drug ibrutinib to standard chemotherapy (R-CHOP) helps control a fast-growing type of lymphoma. It is for 75 adults under 65 who have this specific type and are at high risk of the cancer returning. The goal is to see if this combination k…